These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 16868479)

  • 21. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
    Ishikawa T; Mizuno K; Watanabe K; Baba Y; Oota H; Yoshida T; Kamimura T
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1555-8. PubMed ID: 15508450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
    Xiao JC; Zhang TP; Zhao YP
    Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of human equilibrative nucleoside transporter 1 by RNAi enhances 5-fluorouracil response in pancreatic cancer.
    Hu X; Chen W; Xu J
    Hepatogastroenterology; 2010; 57(104):1567-72. PubMed ID: 21443122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of calmodulin antagonists (W-5 and W-7) on antitumor activity of Tegafur and UFT (Tegafur plus uracil)].
    Kikuchi Y; Oomori K; Iwano I; Kizawa I; Miyauchi M; Kita T; Kato K
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):422-8. PubMed ID: 3131462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhu Y; Qi M; Lao L; Wang W; Hua L; Bai G
    Genet Test Mol Biomarkers; 2014 May; 18(5):306-12. PubMed ID: 24625353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice.
    Haga S; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Fukushima M; Kajiwara T
    Anticancer Res; 1999; 19(3A):1791-6. PubMed ID: 10470117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
    Sekiguchi I; Suzuki M; Tamada T; Nishida M
    Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
    Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
    Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
    Sunagozaka H; Yamashita T; Kagaya T; Kato Y; Kaneko S
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):829-32. PubMed ID: 16770107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
    Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
    Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The modulating effect of interferon alpha-2a on the antitumor activity of UFT against a human gastric carcinoma xenograft, SC-1-NU, in nude mice.
    Kubota T; Kurihara N; Kase S; Watanabe M; Kumai K; Kitajima M; Inada T
    Surg Today; 1996; 26(1):12-4. PubMed ID: 8680114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
    Nakamori S; Tujie M; Takahashi Y; Maruhashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):51-4. PubMed ID: 14750321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
    Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
    World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
    Murata A; Nakata B; Komoto M; Hirata K; Kimura K; Amano R; Hirakawa K
    Hepatogastroenterology; 2013 Sep; 60(126):1484-7. PubMed ID: 23933942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
    Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
    Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
    Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
    PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.